Immorna Receives Grant For MRNA RSV Vaccine Development From Gates Foundation
27 Aug 2024 //
PHARMABIZ
Immorna Gets FDA Clearance For JCXH-211 IV Phase 1/2 Study In Solid Tumors
08 Jul 2024 //
PR NEWSWIRE
Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105
09 Jan 2023 //
PR NEWSWIRE